Publicado

2015-07-01

Cannabis sintético: aspectos toxicológicos, usos clínicos y droga de diseño

Synthetic cannabis: toxicological effects, clinical use and designer drugs

Palabras clave:

Cannabis, Endocannabinoides, Drogas diseñadas, Drogas/efectos de drogas, Enfermedades neurodegenerativas (es)
Cannabis, Endocannabinoids, Designer Drugs, Drugs/drug effects, Neurodegenerative Diseases (en)

Descargas

Autores/as

  • Andrés Felipe Casadiego-Mesa Departamento de Psicología, Facultad de Ciencias Humanas, Universidad Nacional de Colombia. Bogotá, D.C., Colombia.
  • Sara Margarita Lastra-Bello Departamento de Toxicología, Facultad de Medicina, Universidad Nacional de Colombia. Bogotá, D.C., Colombia.

La planta cannabis sativa tiene un largo historial de uso en el transcurso de la humanidad y, desde hace varias décadas, se ha retomado el interés por ella debido a su potencial terapéutico relacionado con diversidad de patologías. Sin embargo, el acercamiento a los aspectos toxicológicos, clínicos y terapéuticos de la planta, y sus derivados sintéticos se ha visto limitado, debido a las connotaciones culturales y legales que existen en la actualidad alrededor de su uso. Pues, dichos derivados sintéticos están siendo utilizados con fines recreativos, exponiendo a gran cantidad de personas a riesgos en su salud. En ese sentido, este artículo expondrá algunas generalidades sobre la planta, el sistema endocannabinoide y sus ligandos, su uso como droga de síntesis y su uso terapéutico, principalmente en las enfermedades neurodegenerativas del Parkinson y el Alzheimer.

The cannabis sativa plant has a long history of use in the course of humanity and, since a few decades ago, has gained attention because of its therapeutic potential associated with diverse pathologies. However, the study of its toxicological, clinical and therapeutical properties, and its synthetic derivatives, has been limited due to cultural and legal connotations about its use. This is because such synthetic derivatives are being used for recreational purposes, exposing many people to health risks. Thus, this article will present some generalities about the plant, the endocannabinoid system and its ligands, its use as synthetic drug and its therapeutical use, especially in neurodegenerative diseases like Parkinson and Alzheimer.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Benito-Sastre C. Estudio neuropatológico y funcional del sistema cannabinoide glial en procesos neuroinflamatorios [Tesis Doctoral]. Madrid:Universidad Complutense de Madrid; 2010.

Reguero-Acebal L. Arquitectura subcelular del sistema endocannabinoide en el núcleo ventromedial del hipotálamo del ratón [Tesis Doctoral]. Leioa: Universidad del País Vasco; 2012.

Rodríguez-Carranza R. Los productos cannabis sativa: situación actual y perspectivas en medicina. Salud Ment. 2012 [cited 2015 Jun 22];35(3):247-56. Spanish. Available from: http://goo.gl/aDXfY3.

Berrendero F. Elementos que conforman el sistema cannabinoide endógeno. En: Sociedad Española de Investigación Sobre Cannabinoides. Guía básica sobre los cannabinoides. Madrid: Universidad Complutense de Madrid; 2009. p. 23-32.

Grotenhermen F. Los cannabinoides y el sistema endocannabinoide. Cannabinoids. 2006 [cited 2015 Jun 22];1(1):10-4. Spanish. Available from: http://goo.gl/Iq8D3t.

Guzmán M, Galve-Roperh I. Endocannabinoides: un nuevo sistema de comunicación en el cerebro. En: Miras-Portugal M, Rodríguez-Artalejo A, editores. Avances en neurociencia: Neurotransmisores y patologías nerviosas. Madrid: Real Academia Nacional de Farmacia; 2009. p. 177-94.

Callén-Herrero L. Expresión, función y heteromerización de los receptores cannabinoides CB2 en el sistema nervioso central [Tesis]. Barcelona: Universitat de Barcelona; 2012.

Pertwee R. Receptores y farmacodinamia: cannabinoides y endocannabinoides naturales y sintéticos. En: Uso terapéutico del cannabis y los cannabinoides. Barcelona: Pharma Editores; 2006. p. 101-35.

Fernández-Ruiz J, González S, Cebeira M, Ramos JA. Bases moleculares y farmacológicas de la tolerancia/dependencia a cannabinoides. Conduct Adict. 2001 [cited 2015 Jun 23];1(1):1-38. Spanish. Available from: http://goo.gl/jzvXu6.

Florido-García V. Expresión de receptores cannabinoides en el desarrollo embrionario del pez cebra [Tesis]. Salamanca: Universidad de Salamanca; 2009.

Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: Moving toward the clinic. Front Pharmacol. 2014 [cited 2015 Jun 23];5:1-11. http://doi.org/5m9.

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol. 2008 [cited 2015 Jun 23];153(2):199-215. http://doi.org/cw5fpm.

González S, Sagredo O, Gómez M, Ramos JA. Química y metabolismo de los cannabinoides. En: Sociedad Española de Investigación Sobre Cannabinoides. Guía básica sobre los cannabinoides. Madrid: Universidad Complutense de Madrid; 2009. p. 13-22.

Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003 [cited 2015 Jun 23];42(4):327-60. http://doi.org/d54kq4.

Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010 [cited 2015 Jun 23];105(3):494-503. http://doi.org/bf3pv6.

Xingdi Hu, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 2011 [cited 2015 Jun 23];6:16-9. http://doi.org/d5m34k.

Wiley JL, Marusich JA, Huffman JW, Balster RL, Thomas BF. Hijacking of basic research: The case of synthetic cannabinoids. Methods Rep RTI Press [Internet]. 2011 [cited 2015 Jun 23]; [about 8 pp.]. Available from: http://goo.gl/eai51a.

Aoun EG, Christopher PP, Ingraham JW. Emerging drugs of abuse: Clinical and legal considerations. R I Med J. 2014 [cited 2015 Jun 23];97(6):41-5. Available from: http://goo.gl/ic3TWx.

James L, Moran JH, Moran C, McCain KR, Oza K. Tips from the clinical experts. K2, Summit and Spice: Fake «weed» is not so nice. MLO Med Lab Obs. 2011 [cited 2015 Jun 23];43(4):36. Available from: http://goo.gl/UbEUE8.

Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013 [cited 2015 Jun 23];32(2):141-6. http://doi.org/5ng.

Antoniou T, Juurlink DN. Synthetic cannabinoids. CMAJ Can Med Assoc J. 2013 [cited 2015 Jun 23];186(3):210. http://doi.org/5nh.

Addy PH, Cyril D'souza D. Commentary on Hermanns-Clausen et al. (2013): Spicing things up - the emerging phenomenon of synthetic cannabinoid use. Addiction. 2013 [cited 2015 Jun 23];108(3):545-6. http://doi.org/5nj.

Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013 [cited 2015 Jun 23];108(3):534-44. http://doi.org/5nm.

Forrester M, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012 [cited 2015 Jun 23];31(10):1006-11. http://doi.org/5np.

Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. «Spice» and «K2» herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012 [cited 2015 Jun 23];21(4):320-6. http://doi.org/5nq.

Evren C, Bozkurt M. Synthetic cannabinoids: Crisis of the decade. Düşünen Adam The Journal of Psychiatry and Neurological Sciences. 2013 [cited 2015 Jun 23];26:1-11. Available from: http://goo.gl/O4GCLh.

United Nations Office on Drugs and Crime. Global Smart Update. 2013 Mar [cited 2015 Jun 23];9. Available from: https://goo.gl/2AvDWv.

Gunderson EW. Synthetic cannabinoids: A new frontier of designer Drugs. Ann Intern Med. 2013 [cited 2015 Jun 23];159(8):563-4. http://doi.org/5nr.

Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012 [cited 2015 Jun 23];39(2):234-43. http://doi.org/5nt.

United Nations Office on Drugs and Crime. Synthetic cannabinoid in herbal products; 2011 [cited 2015 Jun 23]. Available from: https://goo.gl/QXaTKa.

European Monitoring Centre of Drugs and Drug Addiction. Perspectives on drugs: Synthetic cannabinoids in Europe; 2014.

European Monitoring Centre of Drugs and Drug Addiction. Understanding the «Spice» phenomenon; 2009.

De Brabanter N, Deventer K, Stove V, Van Eenoo P. Synthetic cannabinoids: general considerations. P Belg Roy Acad Med. 2013 [cited 2015 Jun 23];2:218-34. Available from: http://goo.gl/NKIwz5.

Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug Alcohol Depend. 2011 [cited 2015 Jun 23];117(2):152-7. http://doi.org/ch5d2z.

Spaderna M, Addy P, D'Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013 [cited 2015 Jun 23];228(4):525-40. http://doi.org/5nv.

Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol. 2012 [cited 2015 Jun 23];8(1):62-4. http://doi.org/bfrw59.

Tung CK, Chiang TP, Lam M. Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry. 2012 [cited 2015 Jun 23];22(1):31-3. Available from: http://goo.gl/JSp2TJ.

Soussan C, Kjellgren A. The flip side of «Spice»: The adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. Nord Stud Alcohol Drugs. 2014 [cited 2015 Jun 23];31(2):207-20. http://doi.org/f23k4r.

Tacoronte-Morales JE, Figueredo YN, Montalbán M, García LM, Suárez HC, Díaz JAM, et al. Canabinoides: análogos y perspectivas terapéuticas II. Cannabinoids Analog Ther Perspect II Engl. 2008 [cited 2015 Jun 23];42(3):1-13. Spanish. Available from: http://goo.gl/ni3JuI.

Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: A Promising drug for neurodegenerative disorders? CNS Neurosci Ther. 2009 [cited 2015 Jun 23];15(1):65-75. http://doi.org/ckgmrc.

Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry. 2009 [cited 2015 Jun 23];21(2):172-80. http://doi.org/ckmjbh.

Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci Ther. 2011 [cited 2015 Jun 23];17(6):637-44. http://doi.org/d94vhn.

Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997 [cited 2015 Jun 23];12(9):913-9. http://doi.org/cmdmm9.

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013;75(2):323-33. http://doi.org/5nw.

García LM, Morales JET, Figueredo YN, Montalbán M, Cabrera Suárez HR. Potencial terapéutico de los canabinoides como neuroprotectores. Ther Potential Cannabinoids Neuroprotective Agents Engl. 2007 [cited 2015 Jun 23];41(3):1-11. Spanish. Available from: http://goo.gl/3ONSDk.

Rocha FCM, Stéfano SC., De Cássia Haiek R, Oliveira LMQR, Da Silveira DX. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. 2008 [cited 2015 Jun 23];17(5):431-43. http://doi.org/b8z8gk.

Zhornitsky S, Potvin S. Cannabidiol in humans--The quest for t therapeutic targets. Pharmaceuticals. 2012 [cited 2015 Jun 23];5(12):529-52. http://doi.org/5nx.

De Mello Schier AR, de Oliveira Ribeiro NP, de Oliveira e Silva AC, Cecilio Hallak JE, Crippa JAS, Nardi AE, et al. Cannabidiol, a cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012 [cited 2015 Jun 23];34(S1):S104-17. http://doi.org/f26qvj.

Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007 [cited 2015 Jun 23];14(3):290-6. http://doi.org/cjqrch.

Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007 [cited 2015 Jun 23];23(1):17-24. http://doi.org/fgth65.

McCarberg BH. Cannabinoids: Their role in pain and palliation. J Pain Palliat Care Pharmacother. 2007 [cited 2015 Jun 23];21(3):19-28. Available from: http://goo.gl/9h6HQA.

Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, et al. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology. 2008 [cited 2015 Jun 23];34(3):672-80. http://doi.org/ch8cwq.

Szczesniak A-M, Maor Y, Robertson H, Hung O, Kelly MEM. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. J Ocul Pharmacol Ther. 2011 [cited 2015 Jun 23];27(5):427-35. http://doi.org/ccf7bk.

Aldana BZ, Medina-Rodríguez I, Tamayo-Pineda N. Cannabinoides y su posible uso en el glaucoma. Rev Cubana de Farm. 2011 [cited 2015 Jun 23];45(3):439-48. Spanish. Available from: http://goo.gl/ASIJLY.

Vanegas H. Acción analgésica de los canabinoides en médula espinal. Analg Action Cannabinoids Spinal Cord Engl. 2010 [cited 2015 Jun 23];12(1):3-10. Spanish. Available from: http://goo.gl/6zC2cy.

Licencia

Derechos de autor 2015 Revista de la Facultad de Medicina

Creative Commons License

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.

-